Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Eli Lilly And Co (LLY) vs Quantumscape Corp (QS) Price & Performance

Eli Lilly And CoTrade
Quantumscape CorpTrade

Price performance (Past 24H)

Key statistics

Eli Lilly And Co vs Quantumscape Corp — how do they compare? Eli Lilly And Co trades at $1,212.8 (market cap $1.08T), while Quantumscape Corp trades at $6.53 (market cap $3.90B). The key difference: Eli Lilly And Co is far larger — about 276.9× Quantumscape Corp's market cap, and Eli Lilly And Co pays a 0.57% dividend while Quantumscape Corp pays none. Which is the better fit depends on your goals.

LLYQS
Market Cap
$1.08T$3.90B
Sector
HealthConsumer Cyclical
52-Week High
$1.24K$18.44
52-Week Low
$639.43$4.89
Enterprise Value
$1.13T$3.11B
Dividend Yield
0.57%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,231.58, up 3.87% in the past 24 hours, reflecting strong momentum near its 52-week high. The stock exhibits bullish technical signals with robust fundamentals, including 48% revenue growth in Q2 2026 and a net income margin of 33.53%. Recent news highlights legal actions against black-market drug sales and positive analyst sentiment following earnings beats.

Outlook remains positive with a consensus price target of $1,380, though high valuation ratios (P/E 40.79) and regulatory risks pose challenges. Earnings growth and pipeline advancements, like retatrutide, drive upside potential, but investors should monitor competitive pressures and execution risks.

Quantumscape Corp

QuantumScape (QS) trades at $6.19, up 1.89% today, with a mixed technical outlook showing bullish oscillators but bearish moving averages. The company remains pre-revenue with significant losses, reporting a net income of -$435.05M in 2025 (company filing, 2025). Recent Q2 2026 earnings beat expectations but highlighted ongoing commercialization delays, with solid-state battery targets pushed to 2029 (The Motley Fool, 2026-08-11).

The stock presents high-risk speculation due to zero revenue and persistent cash burn, offset by potential long-term disruption in battery technology. Analyst sentiment is cautious with 73% hold ratings, reflecting skepticism on near-term execution. Key risks include timeline slippage, funding needs, and competitive pressure in the EV supply chain.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY

About Quantumscape Corp

QuantumScape Corp is engaged in the development of next-generation solid-state lithium-metal batteries for use in electric vehicles. It developed anode-less cell design, which delivers high energy density while lowering material costs and simplifying manufacturing.

Read more on QS